Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Nisreen Khambati of the Oxford Vaccine Group writes for the Oxford Science Blog on why it is vital to find new ways to test children for tuberculosis.

Hands of an adult and a child, holding an illustration of a pair of lungs

Every year, more than one million children fall ill with tuberculosis (TB) globally, and about a quarter die from this potentially preventable and curable disease. According to the World Health Organization, TB is one of the ten most frequent causes of death among children under five years of age.

The main challenge remains the correct and timely diagnosis of TB, especially in resource-constrained settings. TB is more difficult to diagnose in children compared to adults because there are far fewer TB bacteria present in children than in adults. This means that in many children the diagnosis of TB is missed.

To test young children for TB, we currently need to collect mucus from the lungs (sputum) or liquid contents of the stomach which are difficult to obtain from children and must be collected in a hospital. Diagnosis of TB in children with HIV infection is even more difficult and they are more likely to develop TB compared to children not infected with HIV. Despite advances in TB diagnostic tests in the last decade, these have not impacted significantly on paediatric TB. New and different ways to diagnosis TB in children are urgently needed, especially for those infected with or exposed to HIV.

Read the full Oxford Science Blog on the University of Oxford website.

Similar stories

Oxford-led team given £6.6m to map uncharted networks in the progression of Parkinson’s

A major new $9 million (£6.6 million) project funded by the Aligning Science Across Parkinson’s (ASAP) initiative will map the original circuits vulnerable to Parkinson’s on an unprecedented scale. It is the only UK-led ASAP project this year, and the first ever to be led by Oxford.

Tamoxifen repurposing study shows no benefit in treating deadly fungal meningitis

Hopes that tamoxifen could improve survival for a deadly form of fungal meningitis have been dashed by the results of a clinical trial conducted by University of Oxford researchers and published today in eLife.

Oxford researchers awarded funding to complete community COVID-19 antiviral trial

Researchers from the Nuffield Department of Primary Care Health Sciences, University of Oxford, have today announced that they have been awarded funding through the National Institute for Health Research (NIHR) to work with several UK universities and carry out a first-of-its-kind clinical trial, testing novel antiviral COVID-19 treatments for use early on in the illness by people in the community with COVID-19 who are at higher risk of complications.

New therapeutic targets identified to treat inflammatory bowel disease

Millions of patients with ulcerative colitis or Crohn’s disease, collectively known as inflammatory bowel disease (IBD), are given fresh hope as a new study shows why some of them do not respond to current treatments.

Oxford researchers call for an urgent re-evaluation of “weak” opioid safety profile

A new study associates dispensation doses of tramadol with increased risk of mortality, cardiovascular events, and fractures compared to the use of codeine to treat pain.

Labelling proteins through the diet gives new insights into how collagen-rich tissues change as we age

A new study, published in eLife, uses advanced tissue analysis technology to show how the incorporation of new proteins changes in bone and cartilage with age.